News – Page 416 – Endpoints News

ImmunityBio looks to pull in $157M from founder Patrick Soon-Shiong and another investor

3 years ago

Black Diamond spins out antibody work into new biotech with $30M from Versant, NEA

3 years ago

Vertex, Moderna prepare to take their inhaled mRNA cystic fibrosis drug into the clinic

3 years ago

#ASH22: ALX Oncology reports complete response with anti-CD47 candidate in combo trial

3 years ago

#ASH22: Lilly’s Loxo rounds out the PhI/II data for lymphoma drug under FDA review

3 years ago

#ASH22: Cogent touts data on small subset of rare disease patients in bid to compete with Blueprint

3 years ago

GSK chief Emma Walmsley picks out a trim new global HQ in downsizing move

3 years ago

Clovis files for bankruptcy, will keep operating and plans to sell pipeline asset to Novartis

3 years ago

Bill Anderson to step down as Roche pharma chief by month's end

3 years ago

#ASH22 roundup: CSL shows two years of data in $3.5M hemophilia gene therapy; Syndax shows 30% CR rate from March ...

3 years ago

Updated: Horizon's $28B sale to Amgen was kicked off by Sanofi's interest

3 years ago

Updated: Amgen in advanced talks for Horizon, WSJ reports; Sanofi pulls out

3 years ago

#ASH22: Regeneron reveals its first PhII data in contested CD20xC3 bispecific race

3 years ago

#ASH22: Bristol Myers reports next-gen CAR-T data as rival’s bispecific heads to FDA, and gives alnuctamab another ...

3 years ago

#ASH22: Lilly’s Loxo spells out BTK data as it eyes BeiGene, AbbVie/J&J and AstraZeneca

3 years ago

#ASH22: 'Not so surprising': With lack of durability, Affimed scraps monotherapy plans in favor of NK cell combo

3 years ago

#ASH22: J&J touts first PhII results of next-gen multiple myeloma antibody

3 years ago

#ASH22: Kura’s menin inhibitor heads to PhII in subset of acute myeloid leukemia with mixed data

3 years ago

#ASH22: Adicet touts longer-term CR data after ASCO win

3 years ago

Endpoints honors 20 women leaders; Vertex teams up with neighbor; Pfizer rival impresses; and more

3 years ago

Valisure in the hot seat: New Form 483 over a 2021 inspection as CEO fires back

3 years ago

Moving to the employer side of healthcare, Mark Cuban's Cost Plus Drugs partners with a PBM

3 years ago

WIB22: Amber Salzman had few options when her son was diagnosed with a rare genetic disease. So she created a better ...

3 years ago

FDA reviewers head back to White Oak in 2023, with leadership looking to appease a new Congress

3 years ago

First page Previous page 413 414 415416417 418 419 Next page Last page